Si-Bone Inc (SIBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Si-Bone Inc (SIBN) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.33 Million) by net assets ($172.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Si-Bone Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Si-Bone Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Si-Bone Inc total liabilities for a breakdown of total debt and financial obligations.
Si-Bone Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Si-Bone Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Hybribio Biotech Co Ltd
SHE:300639
|
0.018x |
|
Bright Oceans Inter Telecom Corp
SHG:600289
|
-0.196x |
|
Alpha Networks Inc
TW:3380
|
0.008x |
|
Newsmax, Inc.
NYSE:NMAX
|
-0.266x |
|
Yinchuan Xinhua Commercial Group Co Ltd
SHG:600785
|
0.170x |
|
DRB - Hicom Bhd
KLSE:1619
|
0.037x |
|
China Steel Chemical Corp
TW:1723
|
0.052x |
|
Nel ASA
OL:NEL
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Si-Bone Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Si-Bone Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see SIBN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $166.96 Million | $-12.43 Million | -0.074x | +32.64% |
| 2023-12-31 | $169.38 Million | $-18.71 Million | -0.110x | +73.93% |
| 2022-12-31 | $98.30 Million | $-41.66 Million | -0.424x | -44.08% |
| 2021-12-31 | $134.42 Million | $-39.53 Million | -0.294x | -62.45% |
| 2020-12-31 | $169.36 Million | $-30.66 Million | -0.181x | +63.93% |
| 2019-12-31 | $63.01 Million | $-31.63 Million | -0.502x | -211.81% |
| 2018-12-31 | $90.19 Million | $-14.52 Million | -0.161x | -218.81% |
| 2017-12-31 | $-129.38 Million | $-17.53 Million | 0.135x | -12.06% |
| 2016-12-31 | $-108.73 Million | $-16.75 Million | 0.154x | +101.86% |
| 2015-12-31 | $3.23 Million | $-26.72 Million | -8.264x | -116.34% |
| 2014-12-31 | $6.89 Million | $-26.33 Million | -3.820x | -1215.61% |
| 2013-12-31 | $-1.65 Million | $-566.00K | 0.342x | -- |
About Si-Bone Inc
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFu… Read more